RCT proven DTx for cancer patients and survivors suffering from anxiety and depression.

The partnership between DTx companies and pharmaceutical companies has proven to be very powerful when they have synergetic products. Software can boost the effects of drugs and vice versa.

We are providing the opportunity for help in the palm of these patients’ hands during the most profound mental health crisis of our collective generations.

GAIA’s Digital Therapeutics is the future, and we want you to be a part of it. But what exactly goes into this?

Download our white paper created in collaboration with Deloitte to learn about:

• The benefits and increasing interest in DTx as a global solution in reducing the effects of psychological comorbidities and the value of investment in these products.
• How DTx can help win the market amongst the collective scientific companies.
• How GAIA is able to offer a fully automated digital therapeutic treatment, accessible on any connected device 24/7.
• Our company, products, and mission to support the larger scientific research community in providing hope for those that need it most.

Who we are

GAIA AG is the worldwide leader in the development of evidence-based, safe and accessible digital therapeutics. GAIA'S DTx solutions offer the same effect sizes, similar safety profiles and equal levels of convenience as found in well-developed pharmaceutical solutions.

For more than 25 years we have been combining scientific, technological and therapeutic expertise under one roof. Our mission is to increase the quality of people’s wellbeing by helping them to restore and maintain their mental and physical health. The effectiveness of our products has been clinically proven in more than 20 RCTs and 2 meta-analyses.